Search
Upacicalcet
go.drugbank.com/drugs/DB20023InvestigationalUpacicalcet is under investigation in clinical trial NCT05836220 (Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2). Upacicalcet has a monoisotopic molecular weight of 351.03 Da. … Upacicalcet is a small molecule drug. The usage of the INN stem '-calcet/-calcet-' in the name indicates that Upacicalcet is a calcium-sensing receptor (CaSR) agonist.
Atuveciclib
go.drugbank.com/drugs/DB20084InvestigationalAtuveciclib is under investigation in clinical trial NCT02345382 (Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia). Atuveciclib has a monoisotopic molecular weight of 387.12 Da. … Atuveciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atuveciclib is a cyclin dependant kinase inhibitor.
Bavtavirine
go.drugbank.com/drugs/DB21527InvestigationalBavtavirine is under investigation in clinical trial NCT05585307 (Study of Novel Antiretrovirals in Participants With HIV-1). Bavtavirine has a monoisotopic molecular weight of 416.17 Da. … Bavtavirine is a small molecule drug. The usage of the INN stem '-virine' in the name indicates that Bavtavirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
DCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).
Equilin
go.drugbank.com/drugs/DB02187ExperimentalAn estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10774ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10775ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10780ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10782ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.